A second life for MAO inhibitors? From CNS diseases to anticancer therapy

Sabina Sblano,Angelina Boccarelli,Francesco Mesiti,Rosa Purgatorio,Modesto de Candia,Marco Catto,Cosimo D. Altomare
DOI: https://doi.org/10.1016/j.ejmech.2024.116180
IF: 7.088
2024-01-28
European Journal of Medicinal Chemistry
Abstract:Monoamine oxidases A and B (MAO A, B) are ubiquitous enzymes responsible for oxidative deamination of amine neurotransmitters and xenobiotics. Despite decades of studies, MAO inhibitors (MAOIs) find today limited therapeutic space as second-line drugs for the treatment of depression and Parkinson's disease. In recent years, a renewed interest in MAOIs has been raised up by several studies investigating the role of MAOs, particularly MAO A, in tumor insurgence and progression, and the efficacy of MAOIs as coadjutants in the therapy of chemoresistant tumors. In this survey, we highlight the implication of MAOs in the biochemical pathways of tumorigenesis and review the state-of-the-art of preclinical and clinical studies of MAOIs as anticancer agents used in monotherapy or in combination with antitumor chemotherapeutics.
chemistry, medicinal
What problem does this paper attempt to address?